换一批
换一批Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma.
作者：
Ibai,Goicoechea [1]
;
Noemi,Puig [2]
;
Maria-Teresa,Cedena [3]
;
Leire,Burgos [1]
;
Lourdes,Cordón [4]
;
María-Belén,Vidriales [5]
;
Juan,Flores-Montero [2]
;
Norma C,Gutierrez [6]
;
Maria-Jose,Calasanz [7]
;
Maria-Luisa Martin,Ramos [8]
;
David,Lara-Astiaso [9]
;
Amaia,Vilas-Zornoza [2]
;
Diego,Alignani [1]
;
Idoia,Rodriguez [3]
;
Sarai,Sarvide [1]
;
Daniel,Alameda [1]
;
Juan José,Garcés [1]
;
Sara,Rodriguez [1]
;
Vicente,Fresquet [1]
;
Jon,Celay [1]
;
Ramón,Garcia-Sanz [1]
;
Joaquin,Martinez-Lopez [1]
;
Albert,Oriol [1]
;
Rafael,Rios [1]
;
Jesus,Martin-Sanchez [2]
;
Rafael,Martinez-Martinez [3]
;
Josep,Sarra [10]
;
Miguel-Teodoro,Hernandez [11]
;
Javier,de la Rubia [12]
;
Isabel,Krsnik [13]
;
Jose-Maria,Moraleda [14]
;
Luis,Palomera [15]
;
Joan,Bargay [4]
;
Jose-Angel,Martinez-Climent [16]
;
Alberto,Orfao [17]
;
Laura,Rosiñol [18]
;
Maria-Victoria,Mateos [19]
;
Juan-José,Lahuerta [20]
;
Joan,Blade [1]
;
Jesús,San Miguel [5]
;
Bruno,Paiva [21]
作者单位：
Clinica Universidad de Navarra, Centro de Investigación Medica Aplicada (CIMA), Instituto de Investigación Sanitaria de Navarra (IDISNA), Centro de Investigación Biomédica en Red-Cáncer (CIBER-ONC) CB16/12/00369, Pamplona, Spain.
[1]
Hospital Universitario de Salamanca, Instituto de Investigación Biomedica de Salamanca (IBSAL), Centro de Investigación del Cancer, Instituto de Biología Molecular y Celular del Cáncer (IBMCC), Universidad de Salamanca, Consejo Superior de Investigaciónes Científicas (CSIC), CIBER-ONC CB16/12/00233, Salamanca, Spain.
[2]
Hospital 12 de Octubre, CIBER-ONC CB16/12/00369, Madrid, Spain.
[3]
Hospital Universitario y Politécnico La Fe, Valencia, Spain.
[4]
CIBER-ONC CB16/12/00284, Instituto Carlos III, Madrid, Spain.
[5]
Cancer Research Center (IBMCC-CSIC/USAL-IBSAL).
[6]
Cytometry Service (NUCLEUS), and.
[7]
Department of Medicine, University of Salamanca, Salamanca, Spain.
[8]
CIBER-ONC CB16/12/00400, Instituto Carlos III, Madrid, Spain.
[9]
Institut Català d'Oncologia i Institut Josep Carreras, Badalona, Spain.
[10]
Hospital Virgen de las Nieves, Granada, Spain.
[11]
Hospital Universitario Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS)/CSIC/CIBERONC CB16/12/00480, Seville, Spain.
[12]
Hospital Universitario San Carlos, Madrid, Spain.
[13]
Institut Català d'Oncologia (ICO), Hospital Duran i Reynals, L'Hospitalet del Llobregat, Barcelona, Spain.
[14]
Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain.
[15]
School of Medicine and Dentistry, Catholic University of Valencia, Valencia, Spain.
[16]
Hospital Puerta de Hierro, Madrid, Spain.
[17]
Hospital Virgen de la Arrixaca, Murcia, Spain.
[18]
Hospital Clínico Lozano Blesa, Zaragoza, Spain.
[19]
Hospital Son Llatzer, Palma de Mallorca, Spain; and.
[20]
Hospital Clínic Institut D'Investigacións Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain.
[21]
主题词
成年人(Adult);老年人(Aged);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);硼化合物(Boron Compounds);染色体畸变(Chromosome Aberrations);地塞米松(Dexamethasone);抗药性, 肿瘤(Drug Resistance, Neoplasm);女(雌)性(Female);流式细胞术(Flow Cytometry);甘氨酸(Glycine);人类(Humans);男(雄)性(Male);中年人(Middle Aged);多发性骨髓瘤(Multiple Myeloma);肿瘤, 残余(Neoplasm, Residual);治疗结果(Treatment Outcome)
DOI
10.1182/blood.2020006731
PMID
32693406
发布时间
2021-04-16
- 浏览5
Blood
Blood
49-60页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
